Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qiagen ( (QGEN) ) has provided an update.
QIAGEN disclosed that the Dutch financial regulator AFM has published a voting rights notification showing that Goldman Sachs Group Inc. holds a combined 2.93% capital and voting interest in QIAGEN through a mix of direct and indirect positions, including ordinary shares, swaps, warrants, call options and convertible bonds. The complex structure of these real and potential holdings, spread across several Goldman Sachs entities, underscores continued institutional investor activity in QIAGEN’s stock and provides shareholders with greater transparency on significant stake-building in the company.
The most recent analyst rating on (QGEN) stock is a Buy with a $61.00 price target. To see the full list of analyst forecasts on Qiagen stock, see the QGEN Stock Forecast page.
More about Qiagen
QIAGEN N.V., based in Venlo, Netherlands, is a life sciences and diagnostics company whose shares are listed on multiple European exchanges as well as the NYSE and Swiss markets, giving it broad international capital-market exposure.
Average Trading Volume: 1,827,255
Technical Sentiment Signal: Strong Buy
Current Market Cap: $11.17B
For a thorough assessment of QGEN stock, go to TipRanks’ Stock Analysis page.